CLINICAL-STUDY OF RECOVERY AND HALF-LIFE OF VAPOR-HEATED FACTOR-VII CONCENTRATE

被引：12
作者：
RIVARD, GE
KOVAC, I
KUNSCHAK, M
THONE, P
COHEN, LJ
EYSTER, ME
GRIBBLE, TJ
HATHAWAY, WE
KASPER, CK
NEUBERG, R
RUSTAGI, P
SMITH, K
机构：
[1] IMMUNO AG WIEN,CLIN TRIALS,A-1220 VIENNA,AUSTRIA
[2] UNIV MONTREAL,HOP ST JUSTINE,SERV HEMATOL,MONTREAL H3T 1C5,PQ,CANADA
来源：
TRANSFUSION | 1994年 / 34卷 / 11期
关键词：
D O I：
10.1046/j.1537-2995.1994.341195065036.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Background: The in vivo recovery and half-life of intermediate-purity, vapor-heated factor VII (FVII) concentrate were determined in patients having a congenital deficiency for FVII according to the 1991 guidelines of the International Society for Thrombosis and Haemostasis. Study Design and Methods: A total of 11 patients received a single infusion of the FVII concentrate. Blood was drawn before infusion and 15 and 30 minutes and 1,2, 4, 8, 12, and 24 hours after. Recoveries were calculated from the highest FVII activity of the first four blood samples drawn after infusion. The two-phase linear regres- sion method was used to estimate the half-life according to the two-compartment model. In addition, a noncompartmental approach was applied. Results: The mean recovery value obtained for FVII concentrate, 110.53 percent (SD, +/- 26.37), indicates rapid and efficient incorporation into the blood stream. Equivalent results were obtained with both pharmacokinetics methods and indicate a very short half-life for FVII. A half-life of 6.49 hours (SD, +/- 2.42) with the compartmental method and a half-life of 5.25 hours noncompartmental method. Conclusion: The half-life and recovery reported here, along with the specificity of the replacement therapy, the earlier anecdotal cases of clinical efficacy, and the clinical safety of the concentrate with regard to viral infections, recommend vapor-heated FVII concentrate for the treatment of patients with hereditary FVII deficiency.
引用
收藏
页码：975 / 979
页数：5
相关论文
共 50 条
[21]   HALF-LIFE TIME AND CONTROL FREQUENCY OF VITAMIN-K-DEPENDENT COAGULATION-FACTORS - THEORETICAL CONSIDERATIONS ON THE PLACE OF FACTOR-VII IN THE CONTROL OF ORAL ANTICOAGULATION THERAPY [J].
VANDAMMIERAS, MCE ;
HEMKER, HC .
HAEMOSTASIS, 1983, 13 (03) :201-208
[22]   Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor [J].
Elsheikh, Einas ;
Lavin, Michelle ;
Heck, Lilian Antunes ;
Larkin, Niamh ;
Mullaney, Brendan ;
Doherty, Dearbhla ;
Kennedy, Megan ;
Keenan, Catriona ;
Guest, Thomas ;
O'Mahony, Brian ;
Fazavana, Judicael ;
Fallon, Padraic G. ;
Preston, Roger J. S. ;
Gormley, John ;
Ryan, Kevin ;
O'Connell, Niamh M. ;
Singleton, Evelyn ;
Byrne, Mary ;
McGowan, Mark ;
Roche, Sheila ;
Doyle, Mairead ;
Crowley, Maeve P. ;
O'Shea, Susan I. ;
Reipert, Birgit M. ;
Johnson, Jill M. ;
Pipe, Steven W. ;
Di Paola, Jorge ;
Turecek, Peter L. ;
O'Donnell, James S. ;
iPATH study Grp .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (05) :1123-1134
[23]   Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products [J].
Megias-Vericat, J. E. ;
Bonanad Boix, S. ;
Berrueco Moreno, R. ;
Mingot-Castellano, M. E. ;
Rodriguez Lopez, M. ;
Canaro Hirnyk, M. ;
Mateo Arranz, J. ;
Calvo Villas, J. M. ;
Haya Guaita, S. ;
Mesegue Meda, M. ;
Lopez Jaime, F. ;
Albo-Lopez, C. ;
Palomero-Massanet, A. ;
Vilalta Seto, N. ;
Larrode Lecinena, I ;
Cid Haro, A. R. ;
Poveda Andres, J. L. .
THROMBOSIS RESEARCH, 2022, 216 :35-42
[24]   Clinical application of extended half-life factor VIII in children with severe haemophilia A [J].
Dettoraki, Athina ;
Michalopoulou, Aikaterini ;
Mazarakis, Michalis ;
Saslis, Stefanos ;
Stamati, Ioanna ;
Kapsimali, Zoey ;
Pergantou, Helen .
HAEMOPHILIA, 2022, 28 (04) :619-624
[25]   Measurement of extended half-life recombinant factor IX products in clinical practice [J].
Bowyer, Annette E. ;
Shepherd, M. Fiona ;
Kitchen, Steve ;
Maclean, Rhona M. ;
Makris, Mike .
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 (02) :E46-E49
[26]   INVIVO RECOVERY AND HALF-LIFE TIME OF A STEAM-TREATED FACTOR-IX CONCENTRATE IN HEMOPHILIA-B PATIENTS - THE INFLUENCE OF REAGENTS AND STANDARDS [J].
KOHLER, M ;
SEIFRIED, E ;
HELLSTERN, P ;
PINDUR, G ;
MIYASHITA, C ;
MORSDORF, S ;
FASCO, F ;
WENZEL, E .
BLUT, 1988, 57 (06) :341-345
[27]   IN-VIVO RECOVERY AND EARLY HALF-LIFE OF INFUSED FACTOR-VIII IN HEMOPHILIA-A [J].
KASPER, CK .
HAEMOPHILIA, 1995, 1 (01) :14-16
[28]   Use of extended half-life Factor VIII and IX concentrates in haemophilia: a clinical audit [J].
Elder, P. ;
Bailiff, B. ;
Marshall, K. .
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 :191-192
[29]   Clinical outcomes of prophylaxis with extended half-life coagulation factor concentrates or emicizumab in haemophilia [J].
Fernandez Cuezva, L. ;
Gonzalez Resina, R. ;
Obregon Membreno, J. ;
Olivo Moreno, F. ;
Etxebarria Bahillo, L. ;
Villarroya Martinez, L. ;
Ordas Miguelez, M. S. ;
Lopez Gomez, P. ;
Herrero Gutierrez, M. ;
Monleon Gil, R. ;
Cadenas Gota, F. ;
Palacios Orellana, R. ;
Lozada Poveda, D. F. ;
Fernandez Mosteirin, N. ;
Calvo Villas, J. M. .
HAEMOPHILIA, 2024, 30 :111-111
[30]   CLINICAL APPLICATION OF EXTENDED HALF-LIFE PEGYLATED FACTOR VIII IN CHILDREN WITH SEVERE HAEMOPHILIA A [J].
Dettoraki, A. ;
Michalopoulou, A. ;
Mazarakis, M. ;
Saslis, S. ;
Stamati, I. ;
Kapsimali, Z. ;
Pergantou, H. .
HAEMOPHILIA, 2022, 28 :44-45
12345